<u id="65fx9"></u>
WELCOME TO CTTQ PHARMA Leader in the field of liver health, Ranks 4th for Chinese pharmaceutical companies with the best drug pipeline in 2021.

About Us

CTTQ is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales and distribution capabilities. It is the core enterprise of Sino Biopharmaceutical (01177.HK).

With more than 14000 employees, CTTQ is well-known in the field of anti-tumor and liver disease in China. It is ranked 15th on the list of the “Top 100 Pharmaceutical Enterprises in China” in 2020, and among the top 5 most innovative Pharmaceutical Enterprises, and top 10 fastest-growing Pharmaceutical Manufacturers in China.

  • 1969 Founded in 1969, Dongfeng Pharmaceutical Factory
  • 1997 Formed joint venture with Thailand’s Chia Tai Group in 1997
  • 2021 Sales revenue of CTTQ Group reached 3.11 billion dollars in 2021.
Company Profile
We aim to become the pacesetter in the Chinese pharmaceutical industry. We are innovation driven, and focus on R & D to develop new technologies and patented products to improve quality of life and promote human health.
  • product sales

    At present, we manufacture over 50 prescription medicines in 5 core therapeutic areas, including liver diseases, oncology, respiratory diseases, antibiotics and diabetes.

    CTTQ maintains high annual revenue growth in recent years, and its total sales reached 20.72 billion RMB in 2021. Our APIs and FDFs are sold to all major continents including Americas, Europe, Asia, and Africa.
  • R&Dand Intellectual Property

    CTTQ has 2 R&D centers institutes with a total of over 1800 employees. We invest 10%-12% of our annual sales revenue in R&D every year. There are more than 190 projects in our product pipeline, in which State CategoryⅠinnovative drug projects make up more than 40%.

    CTTQ pays special attention to intellectual property and patent protection. By the end of 2020, we have filed 1679 patents, including 1564 inventions. Among them, 586 patents have been granted, including 507 inventions.
  • Our Capabilities

    We currently have 3 manufacturing plants focusing on FDF and API production, 2 R&D centers, 1 overseas branch (CTTQ EU) in Barcelona, Spain, 1 business development office in San Diego, USA, and 4 joint labs (in Shanghai and Chengdu).

    We have 4 solid dosage form and injectable products passed US and EU inspection. CTTQ is the first company that obtained the new version of the Chinese GMP certificate. Our customer base spans over 30 countries.
  • International Collaboration

    The Fulvestrant Injection and Fosaprepitant Dimeglumine for Injection developed by CTTQ has been dispatched to EU and US market. Another co-developed innovative drug, Anlotinib, was designated Orphan Drug status for treatment of ovarian cancer by FDA. Its multiple clinical trials are ongoing for other indications.

    We are looking forward to establishing solid collaborations with partners around the world.

<u id="65fx9"></u>